Navigation Links
Thomson Reuters Helps Brazil's Institute for Applied Economic Research Identify New Opportunities in the Generic Drug Landscape
Date:1/26/2012

PHILADELPHIA and LONDON, Jan. 26, 2012 /PRNewswire/ -- The IP & Science business of Thomson Reuters today announced an agreement with Brazil's Institute for Applied Economic Research (IPEA). This partnership provides IPEA's Direction of Sectorial Studies and Policies for Innovation, Regulation and Infrastructure (DISET) branch with access to the Newport suite of products, supplying them with generic pharmaceutical intelligence as well as with tools for business development and the sourcing of global active pharmaceutical ingredients.

IPEA, a federal public foundation linked to the Strategic Affairs Secretariat of the Brazilian Presidency, provides technical and institutional support to the government for the development of public policies and development programs in Brazil. Within IPEA, DISET performs studies and evaluates public policies on science and technology, innovation, economic regulation, and antitrust.

DISET will use Newport to find new opportunities to improve Brazil's national pharmaceutical infrastructure – in research, development and manufacturing – as well as the quality of its active pharmaceutical ingredients. In addition to the extensive generic drug information available through the Newport suite of products, the group will have access to the Newport Generic Deals module, providing seamless integration of nearly 10,000 generic industry deals since 1999.

"We are enthusiastic about the Newport database," said Professor Eduardo Fiuza, member of the Board of Sector Studies for DISET. "I have never seen so much information about and capabilities for the generic drug market assembled in one single database. It will certainly speed up our data search and contribute to our extensive inquiry on the Brazilian pharmaceutical market. I hope that coverage of Brazilian indicators increases even further in the future."

"This is an exciting time in the evolution of Brazil's pharmaceutical development, and we are pleased to partner with DISET to ensure it meets its goals," said Jon Brett-Harris, executive vice president at Thomson Reuters. "Newport is an essential tool for uncovering new opportunities in the generic drug market, while the mergers and acquisitions data in our Deals module will help pave the way for further economic progress."

The Thomson Reuters Newport suite incorporates unique strategic intelligence and powerful competitive analysis. It integrates intelligence on more than 40,000 launched products containing over 10,000 different active ingredients and over 25,000 corporate groups. Newport Premium is the most advanced product targeting, global business development and API sourcing system from Thomson Reuters, the industry authority on the global generics market. More information is available here.

About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to www.thomsonreuters.com.     


'/>"/>
SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets
2. BryanLGH Medical Center Implements Pharmacy Xpert from Thomson Reuters to Enhance Medication Management
3. Thomson Reuters-NPR Health Poll Finds Three in Four Americans Link Narcotic Pain Killers to Drug Addiction
4. Alabama Selects Thomson Reuters HIE Advantage™ for Statewide Health Information Exchange
5. Thomson Reuters - NPR Health Poll Finds Three-Quarters of Americans Support Government Insurance Subsidies for Birth Control Pills
6. Thomson Reuters Trademark Report Reveals New Challenges and Opportunities for Pharmaceutical Brands
7. Drug Combinations That May Cause Major Drug Interactions Common Among Seniors Who Take Antidepressants, According to Thomson Reuters Research
8. Higher Education Foundation in Brazil Seals Its Continued Relationship with Thomson Reuters for Academic Healthcare Content
9. Asia Pacific Pharma Companies Turning to High-Risk, High-Reward Drug Development, According to New Report from Thomson Reuters
10. Thomson Reuters Unveils Pharmacy Xpert Solution to Improve Medication Management for Hospital Pharmacists
11. Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... France , Germany , Italy ... ). It includes a 10-year epidemiology forecast for the total prevalent ... sex in these markets. GD epidemiology report is written and developed by ... and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... 2016  The Senior Care Pharmacy Coalition (SCPC) ... Chairman Jason Chaffetz (R-UT) and Ranking ... hearing , "Developments in the Prescription Drug Market," ... questions about abusive pharmacy benefit manager (PBM) pricing ... Ranking Member Elijah Cummings (D-MD) are diligent, serious ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
Breaking Medicine Technology:
(Date:2/5/2016)... Seattle, WA (PRWEB) , ... February 05, 2016 ... ... consulting firm, ranked #3 in the 2015 Best in KLAS: Software & Services ... The annual Best in KLAS report independently ranks vendor performance by healthcare ...
(Date:2/5/2016)... ... , ... Stuart Bentkover, MD, FACS is thrilled to announce the ... effective tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts to ... has been approved by the Food and Drug Administration (FDA) as a safe and ...
(Date:2/5/2016)... ... ... In sleep, when the defenses of the day are at rest, rejected emotions ... disorders is significant self-criticism, and consequently these patients experience this disease with their feelings, ... for coping with this unease, but also leads to a reservoir of emotions that ...
(Date:2/5/2016)... Ramsey, NJ (PRWEB) , ... February 05, 2016 ... ... Optimizing Primary Care for Patients with Rare Diseases, a continuing medical education (CME) ... conference is the first of its kind—and a first for ACCORD, whose mission ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
Breaking Medicine News(10 mins):